MILANO (AIMnews.it) – At the Digital Health Summit in Milan, GPI presented the Farmaprice project, developed by GPI in collaboration with the IRCCS CRO of Aviano and Promeditec, with the coordination of the Polo Tecnologico di Pordenone. The aim of the project is to innovate the prescription process of oncological drugs by providing physicians with an IT platform for the management of patient molecular data and translating it into personalised prescription indications, in order to allow, in addition to a more stringent control of health expenditure, greater efficacy of drug therapy, the correct prescription and administration of therapies, the control of the outcomes of the therapies and the insertion of appropriate criteria, all integrated with the Electronic Health Record. The project also includes the creation of a platform for possible use in clinical and molecular research. “The Farmaprice project is a concrete and important step forward towards a new concept of personalised medicine, because it is calibrated to the patient’s genomic data. – explains Lorenzo Giollo, Project Leader, GPI Group – This way you avoid the administration of ineffective or even harmful drugs, with worsening effects as a result, and instead create a therapeutic path with beneficial effects also for the cost of health.” Farmaprice was considered by the Friuli Venezia Giulia region to be of particular scientific interest for clinical and technological innovations and admitted among the projects financed under the POR FESR 2014 – 2020 Call Axis I – Activities 1.3. b – R & D projects to be carried out through private public partnerships in the specialised areas of Smart Health and Maritime Technology based on the 2016 FVG call for funding for industrial research and experimental development.